Candesartan (CHARM-P) 3023 EF >40%; mean age: 67; NYHA class II–IV; prior hospitalization Primary: cardiovascular death; HF-related hospitalization Secondary: composites of primary outcome ...

Although premature ventricular beats (PVBs) in young people and athletes are usually benign, they may rarely mark underlying heart disease and risk of sudden cardiac death during sport. This review ...

Background —The increased risk associated with left ventricular hypertrophy (LVH) diagnosed echocardiographically (Echo-LVH) or electrocardiographically (ECG-LVH) is well known, but the clinically ...

Background Left ventricular hypertrophy (LVH) is associated with multiple cellular electrophysiological abnormalities, susceptibility to ventricular arrhythmias, and an increased risk of sudden death.

Since the early 1990s, prospective epidemiological studies have consistently shown that echocardiographic left ventricular hypertrophy (LVH) is a reliable marker of cardiac remodelling, independently ...

Background Left ventricular hypertrophy (LVH) is the principal cardiac manifestation of Fabry disease (FD). This study aimed to determine the incidence and predictors of LVH development in a ...

Objectives This study tested whether cardiac sympathetic innervation assessed by metaiodobenzylguanidine (MIBG) activity has long-term prognostic value in combination with left ventricular hypertrophy ...

Objectives To investigate: (1) the prevalence of left ventricular hypertrophy (LVH) in elderly primary care patients with long-standing asymptomatic hypertension, and (2) the diagnostic value of ECG ...